Navigation Links
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Date:7/1/2008

riteria) was achieved with the outpatient administration of Dacogen, confirming previously reported response rates in the outpatient setting. The safety profile of this dosing regimen was consistent with what has been previously reported.

Eisai is committed to a clinical development program to optimize the utility of Dacogen for all patients with MDS. Recent studies of hypomethylating agents have suggested that treatment of patients should continue for as long as they receive clinical benefit or until their disease progresses. To advance the understanding of optimal treatment for MDS and related conditions, there are currently more than 30 ongoing trials with Dacogen either as a single agent or in combination with other therapies, including a Phase III survival study in older patients with acute myelogenous leukemia (AML).

Study Design

EORTC-06011: This Phase III open-label, randomized, multi-center, controlled trial evaluated overall survival of patients receiving Dacogen plus BSC versus BSC only. The study involved 233 elderly patients, greater than or equal to 60 years of age, with predominantly high-risk or Intermediate-2 type MDS.

Patients included in the trial had primary or secondary MDS with or without previous therapy with growth factors, immunosuppressive agents or hydroxyurea. In order to participate in the study, patients had to have bone marrow blast counts between 11 and 30 percent. Patients with blast counts below 10 percent were required to have had poor-risk cytogenetics in order to be eligible for randomization.

DACO-020: This is a multi-center, open-label, single arm Phase II study of Dacogen in 99 patients with de novo or secondary MDS. Dacogen was administered daily for five days repeated every four weeks. Patients were greater than or equal to 18 years of age with MDS (de novo or secondary) of any FAB subtype and with an International Prognostic Scoring System score of greater than or equal to 0.5. In order to
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
4. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
5. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
6. Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
7. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
8. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
9. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
10. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
11. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014   Rock Creek Pharmaceuticals, Inc., ... is scheduled to present at the Biotech Showcase™ 2015 ... on January 12-14, 2015. ... Rock Creek Pharmaceuticals, will present preclinical and clinical data ... exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan will outline the ...
(Date:11/21/2014)... 21. November 2014 ... bekannt gegeben, dass die Europäische Arzneimittel-Agentur ... Kennzeichnung als Orphan-Medizinprodukt an Palovarotene vergeben ... zur Behandlung von Fibrodysplasia ossificans progressiva ... beeinträchtigende genetische Krankheit, die von schmerzhaften, ...
(Date:11/21/2014)... 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... Officer, will be presenting at the 26 th Annual ... in New York . The formal presentation ... ET. In addition, Mr. Krakauer and Jorgen B. Hansen ... meetings during the day. An audio webcast ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... ATLANTA, May 25, 2011 XDATA retains Adapt ... patents and fully-functioning prototype focused on breast cancer ... and tested methods and devices for automatically capturing ... validation of the value of XDATA,s patents, leading ...
... as a sort of Huffington Post for the Medical ... offering "Your One Source For Growing Medical Marijuana" for ... worldwide. This first of its kind web ... growing Medical Marijuana and the lifestyle that has arisen ...
Cached Medicine Technology:XDATA Retains Adapt IP Ventures to Market Patents and Technology for Automated 3D Ultrasound Imaging System 2
(Date:11/21/2014)... Mo (PRWEB) November 21, 2014 ... the Get With The Guidelines®–Heart Failure Gold-Plus Quality ... outlined by the American Heart Association/American College of ... heart failure patients. , Get With The Guidelines–Heart ... hospital teams provide the most up-to-date, research-based guidelines ...
(Date:11/21/2014)... VA (PRWEB) November 21, 2014 Launched ... App (ECA) is an all-in-one senior care coordination tool ... on loved ones simple and intuitive for family members ... day care centers). Now, the family caregiver or home ... their daily activities, health data, medical records, goals, schedules, ...
(Date:11/21/2014)... DressVe.com , a renowned women’s dress wholesaler and retailer in ... accessories. Furthermore, the company has launched its Special Black Friday ... its fashion items. Also, orders above $59 are qualified for ... their wedding dresses and prom dresses are very popular in ... , The CEO says “We are glad to introduce ...
(Date:11/21/2014)... 2014 CARE Surrogacy Center in Mexico ... — and at the same time enhancing their surrogacy journey ... for future parents across the globe, the company is reporting ... today are zoning in on the skyrocketing costs of surrogacy ... are individuals over-stressing clinical success rates ? , ...
(Date:11/21/2014)... London, UK (PRWEB) November 21, 2014 ... world’s only ISO verified healthcare professional panel, today announced two ... the appointment of Roni DasGupta as President of Market Research, ... of Market Research, Europe. , Ms. DasGupta joined ... Vice President and most recently Head of Sales. Roni ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4Health News:Comprehensive Senior Care Application Launched on Apple App Store 2Health News:DressVe.com Announces Its 2014 Special Friday Sales 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 3Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2
... pneumonia and gastrointestinal woes , , THURSDAY, Oct. 30 (HealthDay ... age 65 and older resulted in medical and lost ... researchers who analyzed Medicare and National Health Interview Survey ... study were: chronic lung disease, ischemic heart disease, stroke, ...
... 30 Palomar Medical,Technologies, Inc. (Nasdaq: PMTI ... for cosmetic treatments, today announced financial,results for the ... the,quarter ended September 30, 2008 were $24.2 million, ... were royalty revenues, $1.0 million,were funded development revenues, ...
... to Eat Right, Move More and ... Milk Their Diets, ATLANTA, Oct. ... different fad diets -- which seem to go in and out of,fashion like ... Americans -- including 56 percent of Georgia,residents -- remain overweight or obese., ...
... Oct. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ... novel anti-infective products, is scheduled,to announce its financial ... Nov. 13, 2008, before the market opens. At ... conduct a conference call to review the,Company,s third ...
... Ariz., Oct. 30 NaturalNews.com, the independent,natural ... million health-conscious,consumers, has posted audio interviews with ... "Home Safe Home," and Byron Richards, founder ... supplement,provider. Both interviews are available as free ...
... attack rates change when clocks are adjusted , , WEDNESDAY, Oct. ... is just about here, and it may pose problems more ... a jump in the number of heart attacks following the ... spring. , "This was the very first study on this ...
Cached Medicine News:Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 2Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 3Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 4Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 5Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 6Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 7Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 8Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 9Health News:Message to Georgia Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Georgia Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Georgia Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results 2Health News:NaturalNews Posts Audio Interview with Consumer Chemical Expert Debra Lynn Dadd on Bisphenol-A 2Health News:Semi-Annual Time Changes May Affect the Heart 2Health News:Semi-Annual Time Changes May Affect the Heart 3
... basic principle of a competitive enzyme immunoassay ... antigen and an labelled antigen bound to ... antiserum . The amount of enzyme conjugate ... antibody is inversely proportional to the concentration ...
... Progesterone (pregn-4-ene-3, 20-dione) is a C21 ... a double bond between C-4 and C-5 ... hormone which, in conjunction with estrogens, regulates,the ... it is particularly important in preparing the,endometrium ...
Microalbumin Turbidimetric Lipid / Protein Quantification 021-SDX001...
... known as Kininase II, is a dipeptidyl ... of at least 129,000. The structure of ... a polysaccharide residue and a zinc atom. ... types such as neuronal cells and renal ...
Medicine Products: